Summary of the Conference Call for Eddie Pharmaceuticals Company Overview - **Company**: Eddie Pharmaceuticals - **Industry**: Pharmaceutical, specifically focusing on HIV treatment and human protein products Key Points and Arguments Financing and Clinical Development - The refinancing plan has shifted from a simplified procedure to a regular one, increasing the fundraising scale from 185 million to 1.276 billion yuan, with an additional 1.14 billion allocated for global multi-center clinical trials of a new integrase inhibitor [2][3] - Core product 017 has nearly 300 patients enrolled in domestic Phase III clinical trials, targeting 660 patients, with plans to apply for U.S. market entry by March 2026 [2][5] - The company aims to achieve approximately 730 million yuan in revenue in 2025, with a target of 480 million yuan from HIV business in 2026, representing a 70% year-on-year increase [2][13] Sales Strategy and Market Performance - A significant adjustment in sales strategy is planned, with the marketing team expected to expand to 350 members by 2026 [2][15] - January sales reached a record high of over 60,000 boxes, with expectations for Q1 2026 sales to exceed historical peaks of over 82 million yuan [2][16] Clinical Trial Progress and Regulatory Pathways - The company is focused on accelerating patient enrollment for the 017 integrase inhibitor, with a goal to complete enrollment by mid-2026 [5][10] - The international multi-center clinical project is primarily based in the U.S., with plans to submit documentation to the FDA by March 2026 [5][10] - The company anticipates potential adjustments in clinical trial requirements based on FDA feedback, including the possibility of bridge studies [10][11] Financial Projections and Profitability - Revenue projections indicate a significant increase in 2025 and 2026, with expectations of reaching 9 billion yuan in total revenue by 2026 [2][13] - The company aims to achieve profitability in 2026, with a target profit of 75 million yuan, although this may be challenging without successful business development outcomes [14][28] Research and Development Focus - The company is advancing multiple products in the HIV treatment pipeline, including 017, 077, and 085, with specific timelines for clinical trial approvals and market entry [20][23] - The focus on human protein products is expected to yield clinical trial approvals for two products by 2025, with a goal to launch within 3-5 years [24] Strategic Partnerships and Market Positioning - The company is exploring partnerships with multinational corporations (MNCs) for the development of long-acting products, particularly 077 and 085 [8][23] - The recent patent approval for the integrase inhibitor in Japan alleviates concerns regarding potential patent infringements in the U.S. and Europe, facilitating market entry [28] Investor Insights and Future Outlook - Investors are encouraged to focus on the growth trajectory in the HIV sector, with significant changes and catalysts expected in the coming years [28] - The company positions 2026 as a pivotal year for financial performance and operational transformation, with expectations of continued revenue growth and potential profitability [28] Additional Important Information - The company has established a clear timeline for its clinical trials and regulatory submissions, with a focus on maintaining communication with the FDA to ensure compliance and support for its projects [6][10] - The potential for adjustments in the financing plan and the involvement of major shareholders in the fundraising process is highlighted, with a lock-up period of 36 months for the controlling shareholder [7][9]

Core Viewpoint - The company, Eddie Pharmaceuticals, is making significant advancements in the development of HIV treatments, particularly focusing on the new generation of integrase inhibitors and long-acting preventive medications, while also expanding its human protein business. Group 1: HIV Treatment Development - The company has completed a Phase I/IIa clinical study for its new integrase inhibitor, CC017, showing a significant viral load reduction of 2.34 Log10 copies/mL after 10 days of monotherapy, with over 90% of participants achieving complete viral suppression after 18 days of combination therapy [2] - The company reported a 58.49% year-on-year increase in sales revenue for its HIV new drugs, reaching 129 million yuan in the first half of 2025, indicating successful commercialization efforts [3] - The company is actively participating in academic conferences to promote its products and enhance its brand image, while also focusing on patient education and team optimization to improve treatment quality and service processes [3] Group 2: Long-Acting Preventive Medications - The company is accelerating the development of long-acting HIV medications, responding to national strategies for HIV prevention, with two new long-acting drug patents filed and accepted [4] - The market for long-acting medications is expected to grow due to their lower side effects and better privacy, positioning the company to capture a significant share of the pre-exposure prophylaxis (PrEP) market [4] Group 3: Human Protein Business Expansion - The company has established strong relationships with upstream suppliers and is integrating operations following the acquisition of Nanda Pharmaceutical, which has positively impacted its revenue and profitability [6] - The human protein market is growing, with significant advancements in collaboration with Nanda Pharmaceutical, including the approval of new drug applications for innovative human protein products [7] Group 4: Financial Performance - The company's mid-2025 report shows a 100.19% increase in main revenue to 362 million yuan and a 120.23% increase in net profit to 9.19 million yuan [8] - The second quarter of 2025 saw a revenue increase of 86.71% year-on-year, indicating strong financial performance despite some negative net profit figures [8]